Global Non-alcoholic Steatohepatitis (NASH) Diagnostics Market (2018-2023)
The report is sent in 5-10 business days after order is placed.
The global epidemic of type 2 diabetes and rising obesity are leading to the growing prevalence of non-alcoholic steatohepatitis (NASH), especially in developed nations. According to the NASH Education Program, NASH affects around 12% of the world’s adult population. More than 80% of patients with NASH are obese, 44% have type 2 diabetes, and 72% have abnormal blood lipids (triglycerides and cholesterol). The increasing prevalence of these ailments is expected to drive the demand for NASH diagnostics over the 2018-2023 period.
Programs and initiatives to increase awareness are anticipated to bolster market growth over the forecast period. In 2016, The NASH Education Program was established with the objective of spreading awareness among medical practitioners, patients identified with NASH, and individuals at high risk of developing it. On the other hand, rising investments for the development of accurate, reliable, and readily available diagnostic tests for NASH is expected to drive the market over the forecast period.
Diagnostic techniques segment insights:
Liver biopsy is one of the broadly accepted diagnostic techniques for NASH detection since it provides accurate results. Liver biopsy is preferred by medical practitioners owing to its ability to determine the degree of steatosis and inflammation accurately. However, the invasive liver biopsy procedure has several disadvantages, such as pain, bleeding, and the possibility of injuring other organs. Thus, the adoption of non-invasive imaging techniques and biomarkers is anticipated to increase significantly. As a result, the market size of the liver biopsy technique is expected to grow at a slower rate than biomarkers, in developed regions like North America and Europe.
Regional insights:
North America held the largest share of the NASH diagnostics market. The growing prevalence of obesity and type 2 diabetes is leading to an increasing number of patients suffering from NASH in the United States (U.S.) and Canada. NASH has been reported to be the second-most common cause for liver transplantations in the U.S. By 2020, it is expected to surpass hepatitis C as the leading cause for liver transplants. Asia-Pacific is expected to be the fastest growing market owing to increasing awareness among patients and improving healthcare infrastructure. However, the high cost of NASH diagnosis through liver biopsy is restraining the growth of the market in developing regions like Latin America and Asia-Pacific.
Companies covered:
1. GENFIT SA
2. Echosens
3. SuperSonic Imagine
4. BioPredictive
5. One Way Liver, S.L. (OWL)
6. VLVbio AB
7. Quest Diagnostics Incorporated
8. Prometheus Laboratories Inc.
9. Siemens Healthcare GmbH.
10. Exalenz Bioscience Ltd.
Customizations available
With the given market data, Netscribes offers customizations according to specific needs.
The global epidemic of type 2 diabetes and rising obesity are leading to the growing prevalence of non-alcoholic steatohepatitis (NASH), especially in developed nations. According to the NASH Education Program, NASH affects around 12% of the world’s adult population. More than 80% of patients with NASH are obese, 44% have type 2 diabetes, and 72% have abnormal blood lipids (triglycerides and cholesterol). The increasing prevalence of these ailments is expected to drive the demand for NASH diagnostics over the 2018-2023 period.
Programs and initiatives to increase awareness are anticipated to bolster market growth over the forecast period. In 2016, The NASH Education Program was established with the objective of spreading awareness among medical practitioners, patients identified with NASH, and individuals at high risk of developing it. On the other hand, rising investments for the development of accurate, reliable, and readily available diagnostic tests for NASH is expected to drive the market over the forecast period.
Diagnostic techniques segment insights:
Liver biopsy is one of the broadly accepted diagnostic techniques for NASH detection since it provides accurate results. Liver biopsy is preferred by medical practitioners owing to its ability to determine the degree of steatosis and inflammation accurately. However, the invasive liver biopsy procedure has several disadvantages, such as pain, bleeding, and the possibility of injuring other organs. Thus, the adoption of non-invasive imaging techniques and biomarkers is anticipated to increase significantly. As a result, the market size of the liver biopsy technique is expected to grow at a slower rate than biomarkers, in developed regions like North America and Europe.
Regional insights:
North America held the largest share of the NASH diagnostics market. The growing prevalence of obesity and type 2 diabetes is leading to an increasing number of patients suffering from NASH in the United States (U.S.) and Canada. NASH has been reported to be the second-most common cause for liver transplantations in the U.S. By 2020, it is expected to surpass hepatitis C as the leading cause for liver transplants. Asia-Pacific is expected to be the fastest growing market owing to increasing awareness among patients and improving healthcare infrastructure. However, the high cost of NASH diagnosis through liver biopsy is restraining the growth of the market in developing regions like Latin America and Asia-Pacific.
Companies covered:
1. GENFIT SA
2. Echosens
3. SuperSonic Imagine
4. BioPredictive
5. One Way Liver, S.L. (OWL)
6. VLVbio AB
7. Quest Diagnostics Incorporated
8. Prometheus Laboratories Inc.
9. Siemens Healthcare GmbH.
10. Exalenz Bioscience Ltd.
Customizations available
With the given market data, Netscribes offers customizations according to specific needs.
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market scope and segmentation
1.2. Key questions answered
1.3. Executive summary
CHAPTER 2. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) DIAGNOSTICS MARKET – OVERVIEW
2.1. Global market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), geography-wise market revenue (USD Mn), and market attractiveness analysis
2.2. Global market drivers
2.3. Global market trends
2.4. Global market challenges
2.5. Value chain analysis
2.6. Porter's five forces analysis
2.7. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 3. NORTH AMERICA NASH DIAGNOSTICS MARKET
3.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
3.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 4. EUROPE NASH DIAGNOSTICS MARKET
4.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
4.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 5. ASIA-PACIFIC NASH DIAGNOSTICS MARKET
5.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
5.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 6. LATIN AMERICA NASH DIAGNOSTICS MARKET
6.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
6.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 7. THE MIDDLE EAST AND AFRICA NASH DIAGNOSTICS MARKET
7.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
7.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. GENFIT SA
8.1.a. Company snapshot
8.1.b. Product offerings
8.1.c. Growth strategies
8.1.d. Initiatives
8.1.e. Geographical presence
8.1.f. Key numbers
Note: Similar information areas will be covered for the remaining competitors
8.2. Echosens
8.3. SuperSonic Imagine
8.4. BioPredictive
8.5. One Way Liver, S.L. (OWL)
8.6. VLVbio AB
8.7. Quest Diagnostics Incorporated
8.8. Prometheus Laboratories Inc.
8.9. Siemens Healthcare GmbH.
8.10. Exalenz Bioscience Ltd.
CHAPTER 9 CONCLUSION
9.1. Future outlook
Appendix
1. List of tables
2. Research methodology
3. Assumptions
4. About Netscribes Inc.
1.1. Market scope and segmentation
1.2. Key questions answered
1.3. Executive summary
CHAPTER 2. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) DIAGNOSTICS MARKET – OVERVIEW
2.1. Global market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), geography-wise market revenue (USD Mn), and market attractiveness analysis
2.2. Global market drivers
2.3. Global market trends
2.4. Global market challenges
2.5. Value chain analysis
2.6. Porter's five forces analysis
2.7. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 3. NORTH AMERICA NASH DIAGNOSTICS MARKET
3.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
3.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 4. EUROPE NASH DIAGNOSTICS MARKET
4.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
4.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 5. ASIA-PACIFIC NASH DIAGNOSTICS MARKET
5.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
5.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 6. LATIN AMERICA NASH DIAGNOSTICS MARKET
6.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
6.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 7. THE MIDDLE EAST AND AFRICA NASH DIAGNOSTICS MARKET
7.1. Regional market overview historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
7.2. Market segmentation based on diagnostic technique (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. GENFIT SA
8.1.a. Company snapshot
8.1.b. Product offerings
8.1.c. Growth strategies
8.1.d. Initiatives
8.1.e. Geographical presence
8.1.f. Key numbers
Note: Similar information areas will be covered for the remaining competitors
8.2. Echosens
8.3. SuperSonic Imagine
8.4. BioPredictive
8.5. One Way Liver, S.L. (OWL)
8.6. VLVbio AB
8.7. Quest Diagnostics Incorporated
8.8. Prometheus Laboratories Inc.
8.9. Siemens Healthcare GmbH.
8.10. Exalenz Bioscience Ltd.
CHAPTER 9 CONCLUSION
9.1. Future outlook
Appendix
1. List of tables
2. Research methodology
3. Assumptions
4. About Netscribes Inc.
